Note 10 - Warrants	9 Months Ended
Sep. 30, 2019
Notes to Financial Statements
Warrants Disclosure [Text Block]	Note 10. Warrants Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations. On May 3, 2019, in connection with the closing of the Merger, each outstanding Adynxx warrant that had not previously been exercised was converted into a stock warrant to purchase shares of the Company’s common stock at the Exchange Ratio and, as a result, outstanding warrants were converted into warrants to purchase an aggregate of 11,829 shares of the Company’s common stock at an exercise price of $6.34 per share. As such warrants qualify for equity classification, the Company reclassified the balance of $234,000 from warrant liability to additional paid in capital. These warrants are exercisable at any time and expire in 2025 and 2026. Additionally, upon the closing of the Merger on May 3, 2019, the Company assumed outstanding Alliqua warrants to purchase an aggregate of 38,945 shares of common stock at exercise prices ranging from $26.40 to $28.20 per share. These warrants are exercisable at any time and expire in 2022.

Note

10.

Warrants

Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations.

May 3, 2019,

in connection with the closing of the Merger, each outstanding Adynxx warrant that had

not

previously been exercised was converted into a stock warrant to purchase shares of the Company’s common stock at the Exchange Ratio and, as a result, outstanding warrants were converted into warrants to purchase an aggregate of

11,829

shares of the Company’s common stock at an exercise price of

$6.34

per share. As such warrants qualify for equity classification, the Company reclassified the balance of

$234,000

from warrant liability to additional paid in capital. These warrants are exercisable at any time and expire in

2025

and

2026.

Additionally, upon the closing of the Merger on

May 3, 2019,

the Company assumed outstanding Alliqua warrants to purchase an aggregate of

38,945

shares of common stock at exercise prices ranging from

$26.40

$28.20

per share. These warrants are exercisable at any time and expire in

2022.